Just caught something interesting in the latest biotech fund disclosures. Perceptive Advisors went heavy on Praxis Precision Medicines in Q4 2025, dropping $80+ million into the stock and now sitting on a nearly $600 million position. That's their single largest holding at this point.

What caught my eye isn't just the size of the bet, but the timing. Praxis stock is up 320% over the past year, and the fund's position jumped $505 million in value last quarter alone. But here's the thing - they're not just riding winners. They're actively adding to this one. The company just submitted two NDAs to the FDA and has $926 million in cash on the balance sheet plus another $621 million they raised in January. That's a runway into 2028 without needing to hit capital markets.

For a CNS biotech with Phase 3 readouts coming in 2026 and actual FDA submissions already filed, this looks like a fund positioning for near-term catalysts rather than chasing past performance. Praxis is moving from pipeline story to potential commercialization, which changes the risk profile completely. R&D spending hit $267 million in 2025 - they're clearly in execution mode. Worth watching how this plays out over the next 12 months.